ArticleFrontiers in immunology2026
TNFSF10: a promising prognostic biomarker and therapeutic target for immunotherapy in testicular germ cell tumors.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Testicular germ cell tumors (TGCTs) are malignant neoplasms with a poor prognosis, and the absence of reliable biomarkers for patient stratification and diagnosis presents a significant challenge. Methods: We employed an integrated analysis of Single-Cell RNA-Sequencing and TCGA data to evaluate TNFSF10 as a potential biomarker for prognosis and immunotherapy in TGCTs. Results: Our findings revealed that aberrant TNFSF10 expression was significantly associated with patient survival outcomes. Silencing TNFSF10 inhibited the proliferation, migration, and invasion of TGCT cells, highlighting its role in tumor progression. Moreover, TNFSF10 expression was closely correlated with various components of the tumor microenvironment, suggesting its involvement in both the biological behavior of TGCTs and their response to treatment. Conclusion: TNFSF10 emerges as a promising diagnostic and prognostic biomarker for stratification and targeted therapy in TGCTs, offering new prospects for personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.